We are extremely concerned that a decision not to add any new technologies in the 23/24 MedTech Funding Mandate was reached at a time when the NHS is under such unparalleled pressure.
New health technologies and digital innovations, such as the ones already used in the NHS through the Mandate, could provide a much-needed lifeline for the NHS by improving patient outcomes and saving clinicians’ time.
Our CEO, Nicholas Lansman, commented on the decision saying “𝘞𝘩𝘪𝘭𝘴𝘵 𝘪𝘵 𝘪𝘴 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘵𝘩𝘢𝘵 𝘵𝘩𝘦 22/23 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 𝘢𝘳𝘦 𝘱𝘳𝘰𝘱𝘦𝘳𝘭𝘺 𝘪𝘮𝘱𝘭𝘦𝘮𝘦𝘯𝘵𝘦𝘥 𝘢𝘤𝘳𝘰𝘴𝘴 𝘵𝘩𝘦 𝘯𝘦𝘸 𝘐𝘊𝘚 𝘴𝘵𝘳𝘶𝘤𝘵𝘶𝘳𝘦, 𝘵𝘩𝘪𝘴 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘴𝘭𝘢𝘮𝘴 𝘵𝘩𝘦 𝘥𝘰𝘰𝘳 𝘴𝘩𝘶𝘵 𝘰𝘯 𝘯𝘦𝘸 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯𝘴 𝘣𝘦𝘪𝘯𝘨 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘦𝘥 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦𝘭𝘺 𝘢𝘤𝘳𝘰𝘴𝘴 𝘵𝘩𝘦 𝘕𝘏𝘚. 𝘐𝘵 𝘶𝘯𝘥𝘦𝘳𝘮𝘪𝘯𝘦𝘴 𝘵𝘩𝘦 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘪𝘮𝘱𝘳𝘰𝘷𝘦 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩𝘪𝘯 𝘵𝘩𝘦 𝘩𝘦𝘢𝘭𝘵𝘩 𝘴𝘺𝘴𝘵𝘦𝘮 𝘢𝘯𝘥 𝘵𝘩𝘪𝘴 𝘸𝘪𝘭𝘭 𝘩𝘢𝘳𝘮 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴”.